pyrroles and plx4032
pyrroles has been researched along with plx4032 in 7 studies
Research
Studies (7)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Busch, C; de Wijn, R; Geisler, J; Kristensen, V; Lønning, PE; Ree, AH; Risberg, K; Røe, K; Tahiri, A | 1 |
| Cooper, ZA; Ferrone, CR; Ferrone, S; Flaherty, KT; Frederick, DT; Kirkwood, JM; Pepe, S; Pepin, D; Sabbatino, F; Scognamiglio, G; Wang, X; Wang, Y; Wargo, JA; Yu, L | 1 |
| Bollag, G; Graeber, TG; Hu-Lieskovan, S; Koya, RC; Mok, S; Ribas, A; Tsoi, J; West, BL | 1 |
| Chen, YC; Chin, SY; Chou, CL; Jiang, MC; Lee, WR; Liu, KH; Shen, SC; Shih, YH; Tseng, JT | 1 |
| Babagana, M; Bshara, W; Johnson, S; Kandel, ES; Morrison, C; Slabodkin, H | 1 |
| Luo, QY; Qiu, ZL; Shen, CT; Song, HJ; Sun, ZK; Wei, WJ; Zhang, XY | 1 |
| Adderley, T; Christopher, G; Irwin, MS; Kano, Y; Kee, L; Ladumor, Y; Ohh, M; Robinson, CM; Valencia-Sama, I | 1 |
Other Studies
7 other study(ies) available for pyrroles and plx4032
| Article | Year |
|---|---|
Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
Topics: Aged; Cell Line, Tumor; Cluster Analysis; ErbB Receptors; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Mutant Proteins; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Skin; Skin Neoplasms; Substrate Specificity; Sulfonamides; Sunitinib; Vemurafenib | 2013 |
PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzimidazoles; Biphenyl Compounds; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Silencing; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; MAP Kinase Signaling System; Melanoma; Mice; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; RNA, Small Interfering; Sulfonamides; Sunitinib; Up-Regulation; Vemurafenib | 2014 |
Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Indoles; Lymphocyte Activation; Macrophages; Melanoma, Experimental; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Proto-Oncogene Proteins B-raf; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Sulfonamides; T-Lymphocytes; Vemurafenib | 2015 |
Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.
Topics: Animals; Antibodies, Neoplasm; Cell Line, Tumor; Cell Proliferation; Cellular Apoptosis Susceptibility Protein; Colorectal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Lapatinib; Male; Melanoma; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Quinazolines; Sorafenib; Sulfonamides; Sunitinib; Vemurafenib; Xenograft Model Antitumor Assays | 2015 |
P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Indoles; Melanoma; Molecular Targeted Therapy; p21-Activated Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrroles; rac1 GTP-Binding Protein; Sulfonamides; Vemurafenib | 2017 |
Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Drug Resistance; Enzyme Inhibitors; Heterografts; Humans; Indoles; Mice, Nude; Phenylurea Compounds; Protein Multimerization; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyrimidines; Pyrroles; Sulfonamides; Thyroid Neoplasms; Treatment Outcome; Vemurafenib | 2017 |
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Genes, ras; Heterografts; Humans; Indoles; Male; MAP Kinase Signaling System; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Recurrence, Local; Neuroblastoma; Piperidines; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyridones; Pyrimidines; Pyrimidinones; Pyrroles; Triazoles; Vemurafenib | 2020 |